Patents by Inventor Annapurna Pendri

Annapurna Pendri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240238258
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 18, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: HAIBO LIU, YUCHENG MU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LOUIS S. CHUPAK, LAURA AKULLIAN D'AGOSTINO
  • Publication number: 20240228476
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 11, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: HAIBO LIU, YUCHENG MU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LOUIS S. CHUPAK, LAURA AKULLIAN D'AGOSTINO
  • Publication number: 20240207238
    Abstract: Disclosed are compounds of Formula (I): pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
    Type: Application
    Filed: November 8, 2023
    Publication date: June 27, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: ANNAPURNA PENDRI, HAIBO LIU, SHOSHANA L. POSY, YUCHENG MU, JOANNE JEWETT BRONSON, LAURA AKULLIAN D'AGOSTINO
  • Publication number: 20240180886
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
    Type: Application
    Filed: November 8, 2023
    Publication date: June 6, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: YUCHENG MU, HAIBO LIU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LAURA AKULLIAN D'AGOSTINO
  • Publication number: 20230322695
    Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 12, 2023
    Inventors: Haibo Liu, Laura Akullian D′Agostino, Shoshana L. Posy, Annapurna Pendri, Swanee E. Jacutin-Porte
  • Publication number: 20230193260
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: July 27, 2022
    Publication date: June 22, 2023
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. Cacace, Jere E. Meredith, JR., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Patent number: 11447775
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Patent number: 11359197
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • Publication number: 20220119811
    Abstract: The present disclosure relates to antisense oligonucleotides, which target Alpha-synuclein (SNCA) transcript in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder such as a synucleinopathy.
    Type: Application
    Filed: January 11, 2019
    Publication date: April 21, 2022
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Richard E. OLSON, Angela M. CACACE, Marianne Lerbach JENSEN, Jeffrey M. BROWN, Jere E. MEREDITH, JR., Annapurna PENDRI, Ivar M. MCDONALD, Martin GILL
  • Publication number: 20210371860
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of MYH7 in a target cell. The oligonucleotides hybridize to MYH7 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of hypertrophic cardiomyopathy using the oligonucleotide.
    Type: Application
    Filed: May 7, 2019
    Publication date: December 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Richard OLSON, Marianne JENSEN, Annapurna PENDRI, Brian ANDERSON, Sean Carl LITTLE, Linda Jane BRISTOW, John Ryan THOMPSON, Ron AMMAR
  • Publication number: 20210180065
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Publication number: 20200362347
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 19, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Publication number: 20200354720
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 12, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Patent number: 10221129
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 5, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John A. Bender, Robert G. Gentles, Annapurna Pendri, Alan Xiangdong Wang, Nicholas A. Meanwell, Brett R. Beno, Robert A. Fridell, Makonen Belema, Van N. Nguyen, Zhong Yang, Gan Wang, Selvakumar Kumaravel, Srinivasan Thangathirupathy, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Mallikarjuna Rao Mettu, Manoranjan Panda
  • Patent number: 10035760
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth:
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: July 31, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • Publication number: 20180086697
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: April 22, 2016
    Publication date: March 29, 2018
    Inventors: John A. BENDER, Robert G. GENTLES, Annapurna PENDRI, Alan Xiangdong WANG, Nicholas A. MEANWELL, Brett R. BENO, Robert A. FRIDELL, Makonen BELEMA, Van N. NGUYEN, Zhong YANG, Gan WANG, Selvakumar KUMARAVEL, Srinivasan THANGATHIRUPATHY, Rajesh Onkardas BORA, Shilpa Maheshwarappa HOLEHATTI, Mallikarjuna Rao METTU, Manoranjan PANDA
  • Patent number: 9855230
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: January 2, 2018
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: Makonen Belema, John A. Bender, Brett Beno, Robert G. Gentles, Guo Li, Nicholas A. Meanwell, Annapurna Pendri, Zhong Yang, Shirong Zhu
  • Publication number: 20170304239
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
    Type: Application
    Filed: September 3, 2015
    Publication date: October 26, 2017
    Applicant: ViiV Healthcare UK (No.5) Limited
    Inventors: Makonen BELEMA, John A. BENDER, Brett BENO, Robert G. GENTLES, Guo LI, Nicholas A. MEANWELL, Annapurna PENDRI, Zhong YANG, Shirong ZHU
  • Publication number: 20160257645
    Abstract: Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula: (I)
    Type: Application
    Filed: October 23, 2014
    Publication date: September 8, 2016
    Inventors: Annapurna Pendri, Guo Li, John A. Bender, Zhong Yang, Alan Xiangdong Wang, Brett R. Beno, Robert A. Fridell, Makonen Belema, Nicholas A. Meanwell, Robert G. Gentles
  • Patent number: 9034882
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 19, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Annapurna Pendri, David R. Langley, Samuel Gerritz, Guo Li, Weixu Zhai, Stanley D'Andrea, Manoj Patel, B. Narasimhulu Naidu, Kevin Peese, Zhongyu Wang